HilleVax Announces Proposed Public Offering of Common Stock
19 sept. 2023 16h09 HE
|
HilleVax, Inc.
BOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it...
HilleVax Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
14 août 2023 07h00 HE
|
HilleVax, Inc.
BOSTON, Aug. 14, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial...
HilleVax Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
12 mai 2023 16h05 HE
|
HilleVax, Inc.
BOSTON, May 12, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial...
HilleVax Announces Appointment of Nanette Cocero Ph.D., MBA, to its Board of Directors
09 mai 2023 07h00 HE
|
HilleVax, Inc.
BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the...
HilleVax Announces Completion of Enrollment of NEST-IN1 Phase 2b Clinical Study of HIL-214 Norovirus Vaccine Candidate
25 avr. 2023 06h45 HE
|
HilleVax, Inc.
Topline safety and clinical efficacy data from NEST-IN1 expected in the first quarter of 2024 HIL-214 is the most advanced vaccine candidate for norovirus infection There are currently no approved...
HilleVax Reports Full Year 2022 Financial Results and Highlights Recent Company Progress
17 mars 2023 16h05 HE
|
HilleVax, Inc.
BOSTON, March 17, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported...
HilleVax Announces Executive Management Appointments and Promotions
09 janv. 2023 07h00 HE
|
HilleVax, Inc.
BOSTON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the...
HilleVax to Present at the 41st Annual J.P. Morgan Healthcare Conference
04 janv. 2023 16h05 HE
|
HilleVax, Inc.
BOSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it...
HilleVax Announces Positive Immunogenicity Results for Run-In Cohort of NEST-IN1 Phase 2b Clinical Trial of HIL-214 Norovirus Vaccine Candidate
05 déc. 2022 06h30 HE
|
HilleVax, Inc.
BOSTON, Dec. 05, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported results...
HilleVax to Participate in November Investor Conferences
10 nov. 2022 18h30 HE
|
HilleVax, Inc.
BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it...